| 8.79 -0.46 (-4.97%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.36 |
1-year : | 13.78 |
| Resists | First : | 10.58 |
Second : | 11.8 |
| Pivot price | 9.53 |
|||
| Supports | First : | 8.63 |
Second : | 7.18 |
| MAs | MA(5) : | 9.14 |
MA(20) : | 9.61 |
| MA(100) : | 9.65 |
MA(250) : | 9.02  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 18.7 |
D(3) : | 19.2 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 11.8 | Low : | 4.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PRTA ] has closed above bottom band by 6.0%. Bollinger Bands are 8.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.41 - 9.46 | 9.46 - 9.5 |
| Low: | 8.48 - 8.55 | 8.55 - 8.6 |
| Close: | 8.69 - 8.79 | 8.79 - 8.88 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Sat, 06 Jun 2026
(PRTA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Tue, 26 May 2026
[Form 4] PROTHENA CORP PUBLIC LTD CO Insider Trading Activity - Stock Titan
Tue, 26 May 2026
(PRTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fri, 15 May 2026
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Mon, 11 May 2026
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Fri, 08 May 2026
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 3.675e+007 (%) |
| Held by Institutions | 20.2 (%) |
| Shares Short | 7,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.233e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -261 % |
| Operating Margin | 50.4 % |
| Return on Assets (ttm) | -13.8 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.35 |
| Dividend | 0 |
| Forward Dividend | 7.1e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|